Cabazitaxel: risk of bone marrow depression

2015 ◽  
Vol 1534 (1) ◽  
pp. 3-3
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Depression

Radiation Sickness after Therapeutic Administration of 806 mCi of 131I for Thyroid Cancer

1967 ◽  
Vol 06 (02) ◽  
pp. 170-183
Author(s):  
K. Šilink ◽  
J. Němec ◽  
J. Kubal ◽  
S. Röhling ◽  
S. Vohnout
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Radiation Injury ◽  
Clinical Course ◽  
External Irradiation ◽  
Bone Marrow Depression ◽  
Erythroid Hyperplasia ◽  
Cytological Features ◽  
Haematological Changes ◽  
Therapeutic Administration

SummaryThe clinical course and the haematologic events in a patient suffering from metastatic thyroid cancer after administration of 806 mCi of 131I are described. A serious bone marrow depression developed and was treated successfully. The haematological changes during the early and late phases of the radiation injury were studied in detail and compared with those after external irradiation. The haematological events after internal irradiation with 131I are characterised by initial neutrophilic leukocytosis, protracted lymphopenia, slowly developing anaemia reaching lowest values about 3 months after administration, erythroid hyperplasia in the bone marrow after recovery from bone marrow depression and prominent cytological features of the bone marrow, especially pronounced erythropoietic polyploidy.

Outcomes of CAG Regimen for Refractory Biphenotypic Acute Leukemia Patients.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4111-4111
Author(s):  
Guangsheng He ◽  
Xiang Zhang ◽  
Wu Depei ◽  
Aining Sun ◽  
Zhengming Jin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Side Effects ◽  
Cytosine Arabinoside ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Bone Marrow Depression ◽  
Chemotherapy Toxicity ◽  
Lymphoid Lineage ◽  
Stimulating Factor ◽  
Biphenotypic Acute Leukemia

Abstract Abstract 4111 Objective Biphenotypic acute leukemia (BAL) involves both myeloid and lymphoid cells, and there is lack of uniformity in treatment at present. Optimal approach for therapy of BAL is unknown, and BAL usually becomes refractory to conventional chemotherapy. It was found that CAG regimen [low-dose cytosine arabinoside (Ara-C) plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor (G-CSF)] is effective for both myeloid leukemia and refractory acute lymphoblastic leukemia. To explore the efficiency of CAG regimen for refractory BAL, 12 BAL patients who were failed to daunorubicin/mitoxantrone, cytosine arabinoside, vincristine, prednisone (D/MAOP) regimen, were treated by CAG. 8 were males and 4 was female, with ages ranging from 20 to 43 years (median=34 years). Immunophenotype of B lymphoid lineage/myeloid lineage showed in 8 patients, and T lymphoid lineage/myeloid lineage showed in 4 patients. The patients whose blast cells did not decrease 50% after induction regimen with lymphoid and/or myeloid drugs were defined as refractory cases. Methods 12 refractory BAL patients were treated by CAG regimen (cytosine arabinoside 10 mg/m2 subcutaneously every 12 hours, day 1-14; aclarubicin 5-7 mg/m2 intravenously daily, day 1-8; and concurrent use of granulocyte colony-stimulating factor 200μg·m-2·d-1 subcutaneously) from November 2002 to April 2009. The efficacy of the regimen was evaluated by response rate, and the side-effects was also measured. Results The major chemotherapy toxicity was bone marrow depression, mainly showing as pancytopenia. Median duration of absolute neutrophil count (ANC)<0.50×109/L and of platelet (PLT) count<20×109/L was 13 (range, 1-17) days and 1 day (range, 0-5 days), respectively. Median transfusion of red cells and PLT was 4 (range, 1.5-12) U and 20 (range, 0-40) U, respectively. Besides bone marrow depression, other side-effects such as infection, bleeding, nausea and vomiting also occurred during therapy. According to chemotherapy toxicity assessment of WHO, there were 7 patients confronting infection, among whom only 2 patient occurred III-‡W infection. No serious nausea vomiting or hepatic function damage happened. Disclosures: No relevant conflicts of interest to declare.

Dasatinib Drug Use Results Surveys For All Cases As Nationwide Real World Data

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1502-1502
Author(s):  
Yasuhito Nannya ◽  
Kiyohiko Hatake ◽  
Mineo Kurokawa ◽  
Mihoko Nishizawa ◽  
Jumpei Tetsuka ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Adverse Drug Reactions ◽  
Real World ◽  
Research Funding ◽  
Chronic Phase ◽  
Interstitial Lung Diseases ◽  
Fluid Retention ◽  
Drug Reactions ◽  
Bone Marrow Depression ◽  
Blastic Phase

Abstract Introduction Dasatinib is a BCR-ABL kinase inhibitor that was approved in Japan in January 2009 for the treatment of chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). This study was aimed to acquire the background information on the patients treated with dasatinib and early data related to safety and efficacy, which would provide important information to ensure the appropriate use of dasatinib. Methods We conducted the nation-wide surveillance for all the patients who used dasatinib for 3 years after starting this medicine. The target number of patients was 800. The principal aims of the survey were to identify: (1) unknown adverse drug reactions, (2) the circumstances under which adverse drug reactions occur in real-world use of the drug, and (3) the factors that may affect safety and efficacy. Especially, we focused on the circumstances of development and incidences of bone marrow depression/cytopenia, hemorrhage, fluid retention, cardiovascular events and abnormal electrocardiogram (QT prolongation), hepatobiliary disorders, and interstitial lung diseases. Results This survey included 903 evaluable subjects for whom survey sheets have been returned to date, June 27, 2012. The composition of the registered cases was: chronic-phase CML 375, accelerated-phase CML 80, blastic-phase CML 133, Ph+ ALL 312, and others 3. Median age was 62 years (range, 7-92) in the chronic-phase CML group, 63.5 years (range, 9-84) in the accelerated-phase group, 63 years (range, 18-86) in the blastic-phase CML group, and 60 years (range, 5-92) in the Ph+ ALL group. 879 patients were previously treated with imatinib. The proportion of imatinib resistant to imatinib intolerant (resistant/ intolerant) in chronic-phase CML was 57.6%/42.4%, in accelerated-phase CML was 84.0%/16.0%, in blastic-phase CML was 78.4%/21.6%, and in Ph+ ALL was 65.1%/34.9%. The median treatment duration (days) was 414 in the chronic-phase CML group, 303.5 in the accelerated-phase CML group, 81 in the blastic-phase CML group, and 96.5 in the Ph+ ALL group. The frequent adverse drug reactions (10% or more) were thrombocytopenia 45.7%, anemia 36.7%, leucopenia 30.7%, pleural effusion 28.0%, and neutropenia 23.8% (all grades). The incidence of bone marrow depression/cytopenia was 56.1%, hemorrhage 10.7%, fluid retention 37.1%, cardiovascular events and abnormal electrocardiogram 4.5%, hepatobiliary disorders 20.4%, and interstitial lung diseases 3.5%. The incidences of bone marrow depression/cytopenia, hemorrhage, and fluid retention in chronic-phase CML were 49.6%, 5.9%, and 28.8%, respectively, and tended to be lower than in the other phases (accelerated phase and blastic phase CML and Ph+ ALL). Additionally, we will report the intervals before the onset of adverse drug reactions, the circumstances of continuation of administration, and factors that appear to affect safety or efficacy based on the latest data update. Conclusions The information in this all-case drug use results survey will be useful to ensure the appropriate use of dasatinib in real-world patients. Disclosures: Kurokawa: Novartis: Consultancy, Research Funding; Bristol-Myers Squibb: Research Funding; Celgene: Consultancy, Research Funding. Nishizawa:Bristol-Myers K.K.: Employment. Tetsuka:Bristol-Myers K.K.: Employment. Meiji:Bristol-Myers K.K.: Employment. Hiroshi:Bristol-Myers K.K.: Employment.

Reversible bone marrow depression by high‐dose piperacillin/tazobactam

1996 ◽  
Vol 95 (4) ◽  
pp. 611-612 ◽  
Author(s):  
GUILLERMO RUIZ‐IRASTORZA ◽  
GUILLERMO BARREIRO ◽  
CIRIACO AGUIRRE
Keyword(s):  
Bone Marrow ◽  
High Dose ◽  
Bone Marrow Depression
Sign in / Sign up

Export Citation Format

Share Document